Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.
Actively Recruiting
Researchers are evaluating a drug called sigvotatug vedotin SGN-B6A alone and in combination with pembrolizumab, with or without chemotherapy, to assess its safety and effects in people with advanced solid tumors. This Phase 1 study aims to determine the side effects and whether sigvotatug vedotin works to treat various solid tumors including lung, head and neck, breast, esophageal, skin, pancreatic, bladder, cervical, gastric, and ovarian cancers. The study is divided into four parts to explore dosage, safety, and combination treatments. Participants may receive sigvotatug vedotin alone or combined with pembrolizumab, sometimes alongside chemotherapy drugs carboplatin or cisplatin, depending on the study part. Part A focuses on finding the right dose of sigvotatug vedotin. Part B uses this dose to further test safety and effectiveness. Parts C and D study the drug combined with pembrolizumab and possibly chemotherapy in different tumor types and treatment settings, including people who have not previously received treatment. Treatments are given intravenously, with pembrolizumab administered every 3 or 6 weeks and chemotherapy every 3 weeks. During the study, participants undergo tumor biopsies, clinical evaluations, and monitoring for side effects, including blood tests and safety assessments. Researchers track adverse events, lab abnormalities, and dose-limiting toxicities up to 30-37 days after treatment, with some follow-up extending up to 3 years. They also measure tumor response using standard criteria and monitor survival and drug levels in the body. Participants will have regular visits for treatment and assessments throughout the study duration, which may last several years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.
Actively Recruiting
Researchers are studying the safety and how the body processes the medicine Zavegepant PF-07930207 in children aged 6 to less than 12 years who have a history of migraine for at least 6 months. The study focuses on understanding how the medicine is absorbed, changed, and removed from the body after administration. All participants will receive a single dose of Zavegepant as a nasal spray, with the dose depending on their weight. The spray is given once into one nostril. The study will observe the participants experiences, including possible benefits and unwanted effects, during the treatment period. Participants will be involved in the study for up to 10 weeks, which includes 3 visits to the study clinic and 2 follow-up phone calls. Researchers will collect blood samples to measure the medicines levels in the body at specified times and will monitor safety through vital signs, laboratory tests, and questionnaires on mood and behavior.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effectiveness of RGT-419B in people with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. This phase I, open-label study includes participants whose disease has progressed after prior treatment with a CDK46 inhibitor plus hormonal therapy. The study is focused on patients with Stage III locally advanced unresectable or Stage IV metastatic breast cancer. Participants receive RGT-419B either alone as monotherapy or combined with hormonal therapy, including selective estrogen receptor degraders, modulators, or aromatase inhibitors. The study uses escalating oral doses in a sequential design to assess safety and drug behavior. This first-in-human trial includes two experimental arms for comparison between monotherapy and combination therapy. During the study, participants are monitored for dose-limiting toxicities over a 4-week cycle and followed for an average of one year to assess overall safety, drug levels, tumor response, and heart rhythm changes. Researchers collect blood and urine samples for pharmacokinetic analysis and evaluate tumor size using RECIST criteria. The study involves regular assessments to monitor treatment effects and safety throughout participation, which may last up to several years.
Actively Recruiting
Researchers are collecting real-world data on the use of the commercially approved Intracept10 Intraosseous Nerve Ablation Systems to treat patients diagnosed with vertebrogenic pain, including those with chronic low-back pain and vertebrogenic pain syndrome. The study aims to better understand outcomes from this minimally invasive procedure in routine clinical settings. Participants will receive treatment with the Intracept10 Intraosseous Nerve Ablation device following local instructions for use. The study observes patients who undergo this nerve ablation therapy without assigning participants to different groups, as it is an observational study without randomization or placebo. Throughout the study, participants will be monitored over 60 months after the procedure. Researchers will assess changes in disability using the Oswestry Disability Index ODI and gather other outcome data to evaluate the impact of treatment. Participation involves regular follow-up to document treatment effects and safety over time.
Actively Recruiting
This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating MRTX1719 in patients with advanced, unresectable, or metastatic solid tumors that have a homozygous deletion of the MTAP gene. This Phase 1, open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of MRTX1719. The study explores dose and regimen aspects to identify potentially viable treatment approaches. Participants receive MRTX1719, a potent PRMT5-MTA inhibitor, with specified doses administered on certain days. The study begins with dose exploration and may include Phase 1b expansion cohorts to gather additional safety data, pharmacokinetic information, compare effects of food intake, and evaluate bioavailability between capsules and tablets. Early signs of clinical activity are also monitored during these expansions. During the trial, participants undergo mandatory tumor biopsies at baseline and on-study to assess pharmacodynamics unless medically unsafe. Researchers monitor dose-limiting toxicities within 21 days and track treatment-related adverse events for up to 2 years. They also measure objective response rate, duration of response, progression-free survival, and overall survival over 2 years. Laboratory assessments continue for up to 4 years to evaluate long-term effects. This study is sponsored by Bristol-Myers Squibb.
1-10 of 15
1